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The association between the use of tumor necrosis factor-α inhibitors and the increased risk of granulomatous infections, especially
tuberculosis, has been well documented. Given the rapidly expanding list of inflammatory conditions for which tumor necrosis
factor-α inhibitors are receiving FDA approval, the incidence of tuberculosis in this patient population has increased. Despite
heightened awareness by physicians, the diagnosis of tuberculosis can remain challenging, given that extrapulmonary sites of
infection are more frequently involved. We present a case of pulmonary and peritoneal tuberculosis in a gentleman being treated
with a tumor necrosis factor-α inhibitor and discuss the diagnostic challenges of establishing the diagnosis.

1. Introduction
The number of tuberculosis (TB) cases in the United States
(USA) has been falling since the peak in 1992. However since
1992 there has also been a gradual increase of the percentage
of total TB cases that have involved extrapulmonary sites
of infection. Furthermore, the introduction of the tumor
necrosis factor- (TNF-) α inhibitors in 1998 and their rapidly
expanding indication for a variety or rheumatologic conditions have increased the number of cases of TB in patients
treated with these biologic agents, with extrapulmonary sites
of infection being overrepresented. We report a case of both
pulmonary and peritoneal TB in a patient being treated with
adalimumab that illustrates some of the challenges associated
with making this diagnosis in this patient population.

2. The Case
A previously healthy 28-year-old man with a history of
extensive plaque psoriasis on treatment with subcutaneous
adalimumab for over two years presented to the infectious
diseases clinic with a two month history of low-grade fevers,

myalgias, and a severe nonproductive cough. The patient
had been treated with a course of doxycycline followed
by azithromycin approximately one month earlier, causing
temporary improvement in his symptoms.
The patient had emigrated from Vietnam 11 years
previously. The patient’s grandfather had been treated for
pulmonary mycobacterium tuberculosis (MTB) in Vietnam
15 years previously, and the patient had been treated for
latent tuberculosis with nine months of isoniazid in 2004.
The patient lived in Washington, DC, worked in a healthcare
setting, was a nonsmoker, had no pets, and had never
received a pneumococcal vaccine.
Outpatient evaluation by a pulmonologist three weeks
previously included unremarkable laboratory studies and
clear chest X-ray. On evaluation in our clinic, the patient
was noted to be nontoxic appearing and able to speak in
full sentences. His temperature on initial evaluation was
37.2◦ C, blood pressure 109/73 mmHg, heart rate 85 beats
per minute, and respiratory rate 14 breathes per minute.
His lung examination was unremarkable with clear breath
sounds bilaterally without rhonchi or wheezes.
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A computed tomography (CT) scan of the chest performed the same day showed a 1.1 cm lobular opacity in
the right lower lobe, a moderate right pleural eﬀusion
(Figure 1), hilar lymphadenopathy, and a small amount of
perihepatic and perisplenic ascites. Due to the concern for
tuberculosis, the patient was admitted to the hospital for
further evaluation.
On hospital admission, his temperature was 39◦ C, blood
pressure 121/87 mmHg, heart rate 95 beats per minute, and
respiratory rate 22 breathes per minute, with an oxygen
saturation of 97% on ambient air. Physical exam was notable
for bilateral crackles in his lungs and a diﬀuse psoriatic
rash. A CT scan of the abdomen and pelvis performed
with intravenous contrast revealed diﬀuse nodularity of
the omentum and peritoneal lining (Figure 2), raising the
concern for tuberculous peritonitis (TBP).
On the second hospital day, the patient underwent
an unremarkable bronchoscopy and a thoracentesis which
revealed serosanguinous pleural fluid. The pleural fluid was
exudative with an 80% lymphocytic predominance. No acid
fast bacilli (AFB) were seen. The pleural fluid adenosine
deaminase (ADA) was elevated at 110.3 u/L. A subsequent
percutaneous peritoneal biopsy was performed revealing
bloody peritoneal fluid. Grocott’s methenamine silver stain,
AFB stain, Fite’s stain, and mucin stains on the fluid were
negative. Surgical pathology revealed necrotizing granulomatous inflammation with no AFB seen on Auraminerhodamine stain. The patient was empirically started on
isoniazid, rifampin, pyrazinamide, and ethambutol based on
the imaging and pathology results.
The patient underwent an abdominal laparoscopy one
week after admission in an attempt to make a definitive
diagnosis. This revealed extensive peritoneal and omental
studding measuring 2 to 3 mm in size. A modest amount of
bloody ascites was present. Pathology revealed granulomatous inflammation and one AFB on Fite’s stain but no AFB
on Auramine-rhodamine stain. Growth of MTB complex
was noted from the percutaneous peritoneal biopsy after 16
days, and subsequently all other culture specimens showed
growth by day 30. Sensitivities revealed no antimicrobial
resistance.
The patient was continued on his four drug MTB
therapy, but the rifampin was discontinued after 2 weeks due
to drug-induced hepatitis. Once his hepatitis had resolved,
the rifampin was restarted without further transaminitis.
He completed 2 months of directly observed therapy with
isoniazid, rifampin, pyrazinamide, and ethambutol and a
further 7 months of isoniazid and rifampin. He has made a
full recovery.

3. Discussion
In 2011, a total of 10,521 new MTB cases were reported
in the United States (USA). This incidence of 3.4 cases per
100,000 population is the lowest number of reported cases
since reporting began in the USA in 1953 [1]. Foreignborn persons and racial/ethnic minorities remain disproportionately aﬀected with the rate of tuberculosis being 12
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Figure 1: CT scan of the chest showing a 1.1 cm lobular opacity in
the right lower lobe and a moderate right pleural eﬀusion.

Figure 2: CT scan of the abdomen and pelvis showing ascites with
diﬀuse nodularity of the omentum and peritoneal lining.

times greater in foreign-born persons and 25 times greater
in non-Hispanic Asians. In 2010, 22% of reported cases
were extrapulmonary alone, while 78% of reported cases had
evidence of pulmonary disease [2].
The peritoneum is reported as the sixth most common
site of involvement for extrapulmonary MTB [3]. The
symptoms of abdominal MTB develop insidiously over
weeks to months, with the average duration of symptoms to
be 1.5 months [3, 4]. The most common signs and symptoms
included abdominal pain, fever, ascites, and weight loss [3–
7]. Surprisingly our patient had no abdominal symptoms
at presentation. Pulmonary symptoms are reported in only
12% of cases [4].
A variety of imaging modalities can detect ascites and
omental thickening seen in TBP. Ascites is seen radiographically in 30%–100% of cases [8]. Ultrasound is useful for
demonstrating ascites as well as occasionally detecting the
omental calcifications seen in TBP. CT scans are superior for
showing omental changes, such as nodularity or thickening,
which are noted in 36–82% of cases [6], although these
findings can also been seen in peritoneal carcinomatosis.
Sanai and Bzeizi documented abnormal chest radiography in 38% of 1002 cases they reviewed [3], but other studies
have suggested that active pulmonary disease is present in
only 14% of patients with TBP [9]. Pleural eﬀusions are also
commonly associated with abdominal MTB. A retrospective
study of 35 cases of TBP from Taiwan showed that 62%
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had pleural eﬀusions on CXR [10]. Given the wide variation
in clinical and radiographic presentation of the disease,
no single radiographic is adequate to definitively diagnose
peritoneal TB on imaging alone.
Culture of the tuberculous bacilli from an intraabdominal clinical specimen is diagnostic for TBP. However
mycobacterial culture of ascitic fluid was positive in only 35%
of 446 patients reviewed from 22 studies [3], although yields
were significantly better with large volume taps of greater
than 1 liter (66%–83%) [3].
The current gold standard for establishing the diagnosis
of TBP is obtaining mycobacterial cultures from either the
peritoneal or omentum. Open laparoscopy has been shown
to be superior to percutaneous peritoneal biopsy for obtaining these culture specimens, since laparoscopy allows for
macroscopic visualization of the peritoneum. Laparoscopic
examination can reveal whitish nodules scattered throughout
the peritoneum along with ascites, thickened omentum and
thickened bowel loops, or yellowish nodules with adhesions
[11]. Histology can show AFB on staining in up to 75%
of cases and caseating granulomas seen in 85%–90% of
cases [12]. Data from 402 patients in 11 studies showed
a sensitivity and specificity of 93% and 98%, respectively,
when the macroscopic appearances are combined with either
the histological findings of caseating granulomas or the
identification of mycobacteria on special staining [3]. In
this case the peritoneal tissue specimens obtained both
percutaneously and via open laparoscopy, as well as the
ascitic fluid, pleural fluid, and the bronchial alveolar lavage
fluid eventually grew MTB.
Since the approval of the first TNF-α inhibitor in
1998, there has been a noticeable rise in the incidence of
tuberculous infections in this patient population [13] with
a greater proportion of these cases having been extrapulmonary compared with the general population [13]. This
highlights the role of TNF-α in controlling the spread of
mycobacterial infections. MTB infectionsresult in activation
of macrophages which, as a result, secret proinflammatory
cytokines including TNF-α, which is vital for granuloma
formation [14]. TNF-α promotes further macrophage activation, which in turn stimulates phagocytosis of the bacilli [14].
Necrosis within the granuloma results in a poor environment
for the bacterial growth. Since TNF-α inhibitors interfere
with the formation of granulomas required to contain certain
infections, there is a subsequent increased susceptibility to
develop infections due to fungi and mycobacteria in this
population. Furthermore, TNF-α inhibitors have also been
shown to cause T-cell death and monocytopenia, both of
which are also necessary for granuloma formation and
further reducing immunity against such infections [14].
In 2004, the Adverse Event Reporting System of the
FDA highlighted the increased incidence of MTB in patients
being treated with TNF-α inhibitors. Through 2002, the FDA
reported an MTB incidence of 144 per 100,000 patients
treated with infliximab and 35 per 100,000 patients treated
with etanercept [15]. Adalimumab only gained FDA approval
in December 2002 and was, therefore, not included in this
report. However, during clinical trials of adalimumab, 13
cases of TB were reported including miliary, peritoneal,
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lymphatic, and pulmonary infections [16]. A large UK
prospective study compared the rates of MTB amongst
the three approved TNF-α inhibitors, using data from a
large registry of biological treatments used in patients with
rheumatoid arthritis [13]. Adalimumab showed the highest
incidence of MTB (144 events per 100,000 person years),
followed by infliximab (136 events per 100,000 person years),
with etanercept having the lowest incidence (39 events per
100, 000 person years) [17].
One possible explanation for the diﬀerence in MTB
incidence with these agents is related to their degree of
TNF-α blockade. Etanercept only binds soluble TNF-α, while
adalimumab and infliximab bind soluble, transmembrane,
and receptor-bound TNF in an irreversible manner [18]. It is
theorized that the partial rather than complete TNF blockade
may allow for some preservation of the beneficial and antiinflammatory functions of TNF-α in tuberculosis immunity
thereby reducing the incidence of tuberculosis [19].
In conclusion, while it has been well established that there
is an increased risk for reactivation of TB in patients being
treated with TNF-α inhibitors, especially in extrapulmonary
locations, it often remains challenging to definitively establish this diagnosis. Clinicians need to maintain a high index
of suspicion and should aggressively pursue tissue specimens
for microbiologic culture and histology. Our case highlights
a patient who had both pulmonary and peritoneal TB who
did not present with the classic pulmonary or peritoneal
symptoms. However, a high index of suspicion by the
evaluating physician prompted appropriate radiographic and
surgical evaluation, which ultimately revealed the underlying
mycobacterial infection.
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